| P50 | author | David Andes | Q75205210 |
| P2093 | author name string | Alexander J Lepak | |
| P2860 | cites work | Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases | Q24542404 |
| | Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin | Q24674839 |
| | Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis | Q28260867 |
| | Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial) | Q28298468 |
| | Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis | Q28333673 |
| | Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia | Q28349552 |
| | Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial | Q28359772 |
| | Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits | Q28369150 |
| | In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods | Q28372129 |
| | Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis | Q28727508 |
| | Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis | Q30433949 |
| | Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism | Q30853962 |
| | Alcohol dehydrogenase restricts the ability of the pathogen Candida albicans to form a biofilm on catheter surfaces through an ethanol-based mechanism | Q33247523 |
| | Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy | Q33357288 |
| | Effect of nikkomycin Z and 50% human serum on the killing activity of high-concentration caspofungin against Candida species using time-kill methodology | Q84041489 |
| | In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model | Q36932989 |
| | Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients. | Q36936353 |
| | Bioluminescent Aspergillus fumigatus, a new tool for drug efficiency testing and in vivo monitoring of invasive aspergillosis | Q36974215 |
| | Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints | Q37026726 |
| | Significance of Serum Protein and Tissue Binding of Antimicrobial Agents | Q37034927 |
| | Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. | Q37119650 |
| | Clinical practice: combination antifungal therapy for mold infections: much ado about nothing? | Q37157881 |
| | Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin | Q37190801 |
| | Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis | Q37204192 |
| | Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis | Q37247452 |
| | Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates | Q37263430 |
| | Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model | Q37263435 |
| | Antifungal therapeutic drug monitoring: established and emerging indications | Q37310029 |
| | The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates | Q37320912 |
| | Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus. | Q37335649 |
| | THE SLOW RECOVERY OF BACTERIA FROM THE TOXIC EFFECTS OF PENICILLIN. | Q37376712 |
| | Diagnostic imaging of experimental invasive pulmonary aspergillosis | Q37404687 |
| | Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside | Q37578647 |
| | Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications | Q37712057 |
| | Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma | Q37761047 |
| | Pharmacokinetics, pharmacodynamics, and Monte Carlo simulation: selecting the best antimicrobial dose to treat an infection | Q37803080 |
| | Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents | Q37829260 |
| | Protein binding: do we ever learn? | Q37871252 |
| | Pharmacokinetics and tissue penetration of fluconazole in humans | Q37918375 |
| | Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents | Q37927017 |
| | Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. | Q37993043 |
| | The Eagle-like effect of echinocandins: what's in a name? | Q38153458 |
| | Protein binding and its significance in antibacterial therapy | Q38681616 |
| | Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B. | Q39472116 |
| | Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens | Q39652421 |
| | Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis | Q39652561 |
| | Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits | Q39851052 |
| | Transcriptional regulation of chitin synthases by calcineurin controls paradoxical growth of Aspergillus fumigatus in response to caspofungin | Q39895162 |
| | Influence of binding on the pharmacologic activity of antibiotics | Q39899627 |
| | Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations | Q39954432 |
| | Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy | Q40186278 |
| | Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. | Q40528020 |
| | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. | Q36425025 |
| | Bone marrow toxicity associated with 5-fluorocytosine therapy | Q36459546 |
| | Assessment of serum (1->3)-beta-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis. | Q36482821 |
| | Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis | Q36505539 |
| | In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus. | Q36558484 |
| | Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis | Q36584655 |
| | Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture | Q36744831 |
| | Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum | Q36757617 |
| | Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis | Q36757621 |
| | Pharmacokinetics and pharmacodynamics of antimicrobials | Q36854798 |
| | Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te | Q36855581 |
| | Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations | Q36856930 |
| | Association of fluconazole pharmacodynamics with mortality in patients with candidemia | Q36870712 |
| | Activity of posaconazole in treatment of experimental disseminated zygomycosis. | Q36880761 |
| | Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis | Q33449819 |
| | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. | Q33613758 |
| | Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model | Q33693370 |
| | Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. | Q33695281 |
| | Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase | Q33754208 |
| | Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice | Q33806127 |
| | Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice | Q33826450 |
| | Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. | Q33830384 |
| | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species | Q33876423 |
| | Population pharmacokinetics of micafungin in neonates and young infants | Q33876608 |
| | Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system | Q33908389 |
| | Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. | Q33938082 |
| | Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model | Q33977551 |
| | In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model | Q33979115 |
| | Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans | Q33979304 |
| | In vivo activity of amphotericin B lipid complex in immunocompromised mice against fluconazole-resistant or fluconazole-susceptible Candida tropicalis | Q33980705 |
| | Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. | Q33980741 |
| | Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis | Q33981387 |
| | Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model | Q33981712 |
| | Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling | Q33983159 |
| | Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate | Q33983618 |
| | Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis | Q34006585 |
| | Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. | Q34020746 |
| | Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia | Q34104748 |
| | Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods. | Q34105231 |
| | Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits | Q34108880 |
| | Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity | Q34228214 |
| | In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies | Q34253266 |
| | Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis | Q34290034 |
| | Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. | Q34307105 |
| | Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis | Q34352109 |
| | Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models | Q34352186 |
| | Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints | Q34431984 |
| | Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi | Q34455495 |
| | The yeast cell-wall salvage pathway | Q34500169 |
| | Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome | Q34510359 |
| | Multidimensional volumetric imaging of pulmonary infiltrates for measuring therapeutic response to antifungal therapy in experimental invasive pulmonary aspergillosis | Q34510443 |
| | Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis | Q34719835 |
| | Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy | Q34754956 |
| | In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model | Q34881309 |
| | In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model | Q34881676 |
| | Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis | Q35007030 |
| | In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis | Q35091285 |
| | Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations | Q35091593 |
| | Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates | Q35120311 |
| | Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis | Q35127833 |
| | Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect | Q35127913 |
| | Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. | Q35136891 |
| | Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients | Q35270270 |
| | Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics | Q35372178 |
| | Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis | Q35535337 |
| | Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation | Q35582365 |
| | Clinical pharmacodynamics of antifungals. | Q35623090 |
| | Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia | Q35635693 |
| | Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia | Q35647785 |
| | Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach. | Q35689202 |
| | Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. | Q35758926 |
| | Detection and measurement of fungal burden in a guinea pig model of invasive pulmonary aspergillosis by novel quantitative nested real-time PCR compared with galactomannan and (1,3)-β-D-glucan detection | Q35806998 |
| | Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata | Q35867789 |
| | Clinical utility of antifungal pharmacokinetics and pharmacodynamics. | Q36004448 |
| | In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. | Q36048229 |
| | Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing | Q36094957 |
| | Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia | Q36094974 |
| | Monitoring and impact of fluconazole serum and cerebrospinal fluid concentration in HIV-associated cryptococcal meningitis-infected patients | Q36161724 |
| | Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration. | Q36171643 |
| | Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012 | Q36172242 |
| | Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations | Q36364100 |
| | Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways. | Q40668367 |
| | In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models | Q40882541 |
| | In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp | Q41091429 |
| | Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging. | Q41441699 |
| | Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. | Q41696128 |
| | The PKC, HOG and Ca2+ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans. | Q41810708 |
| | Combination echinocandin-polyene treatment of murine mucormycosis | Q41904884 |
| | Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization. | Q41929256 |
| | Paradoxical effect of caspofungin against Candida bloodstream isolates is mediated by multiple pathways but eliminated in human serum | Q41963359 |
| | Posaconazole prophylaxis in experimental systemic zygomycosis | Q42078170 |
| | Assessment of the paradoxical effect of caspofungin in therapy of candidiasis | Q42090519 |
| | Changes in cell wall synthesis and ultrastructure during paradoxical growth effect of caspofungin on four different Candida species. | Q42111171 |
| | Posaconazole mono- or combination therapy for treatment of murine zygomycosis | Q42183489 |
| | Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. | Q42286250 |
| | Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect | Q42577557 |
| | New drugs for the systemic mycoses: flucytosine and clotrimazole | Q43056358 |
| | Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. | Q43189988 |
| | The effects of an hsp90 inhibitor on the paradoxical effect | Q43275008 |
| | Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections | Q43287630 |
| | Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study | Q44396642 |
| | Evaluation of the post-antifungal effect (PAFE) of amphotericin B and nystatin against 30 zygomycetes using two different media. | Q44459191 |
| | Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin | Q44469440 |
| | Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection | Q44866472 |
| | Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis | Q45063490 |
| | Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity | Q45066131 |
| | Continuous infusion of amphotericin B deoxycholate for the treatment of life-threatening Candida infections. | Q45399160 |
| | A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. | Q46023744 |
| | Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). | Q46306343 |
| | Studies of the paradoxical effect of caspofungin at high drug concentrations | Q46377599 |
| | Comparison of the EUCAST-AFST broth dilution method with the CLSI reference broth dilution method (M38-A) for susceptibility testing of posaconazole and voriconazole against Aspergillus spp. | Q46444751 |
| | Twenty-four hour continuous infusion of amphotericin B for the treatment of suspected or proven fungal infection in haematology patients | Q46489287 |
| | Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis | Q46729762 |
| | Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis | Q46819795 |
| | Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis | Q46971553 |
| | Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints. | Q47568169 |
| | In vitro model of invasive pulmonary aspergillosis in the human alveolus | Q47571487 |
| | Candida urinary tract infections--treatment. | Q51175452 |
| | Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus. | Q51175502 |
| | The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis. | Q52896107 |
| | In vitro interaction of fluconazole and amphotericin B administered sequentially against Candida albicans: effect of concentration and exposure time. | Q53727517 |
| | Comparison of three methodologies for the determination of pulmonary fungal burden in experimental murine aspergillosis. | Q54614663 |
| | EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia–forming moulds | Q56837279 |
| | Flucytosine therapeutic monitoring: 15 years experience from the UK | Q56837289 |
| | Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis | Q56993324 |
| | The postantibiotic effect | Q69011396 |
| | Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels | Q69365263 |
| | Postantibiotic effects | Q70073524 |
| | In vivo postantibiotic effect in a thigh infection in neutropenic mice | Q70370760 |
| | The postantibiotic effect of antifungal agents against common pathogenic yeasts | Q72807287 |
| | In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods | Q73516074 |
| | Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation | Q80231148 |
| P433 | issue | 5 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| | pharmacodynamics | Q725307 |
| P304 | page(s) | a019653 | |
| P577 | publication date | 2014-11-10 | |
| P1433 | published in | Cold Spring Harbor Perspectives in Medicine | Q21042440 |
| P1476 | title | Antifungal pharmacokinetics and pharmacodynamics | |
| P478 | volume | 5 | |